Colorectal cancer is projected to impact more than 158,000 Americans in 2026. Learn about an immunotherapy-based treatment ...

Inhibrx Biosciences recently reported updated interim Phase 1/2 data showing that ozekibart (INBRX-109) plus FOLFIRI produced a 20% objective response rate, 5.5-month median progression-free survival ...

Ongoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination ...

Shares of Inhibrx Biosciences INBX rallied 36.9% on Wednesday. The massive surge was triggered by encouraging updated interim ...

Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United StatesVANCOUVER, ...

A French study found that among patients under 40 with early-onset colorectal cancer, multiple-site metastases increased by 10% annually from 2004 to 2021, with no survival improvement for those with ...

Inhibrx Biosciences (NASDAQ:INBX) shared a clinical update on ozekibart in advanced colorectal cancer, highlighting Phase I/II data evaluating ozekibart in combination with FOLFIRI in a heavily pretre ...

In the STELLAR-303 trial, zanzalintinib plus atezolizumab significantly reduced the risk of death by 20% compared with regorafenib in the ITT population. The Food and Drug Administration (FDA) has ...

NGS utilization increased over time but left substantial proportions untested across metastatic breast, prostate, pancreatic, ...

Six of eight patients (75%) with HER2-positive rectal adenocarcinoma responded to trastuzumab and tucatinib plus chemotherapy ...